Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Manidipine hydrochloride |
EINECS | 680-304-3 |
CAS No. | 89226-75-5 | Density | N/A |
PSA | 116.93000 | LogP | 6.48280 |
Solubility | Soluble in DMSO. Slightly soluble in water and ethanol /n | Melting Point |
157-163°; mp 174-180°; mp 167-170° |
Formula | C35H38N4O6.2HCl | Boiling Point | 722 °C at 760 mmHg |
Molecular Weight | 683.632 | Flash Point | 390.4 °C |
Transport Information | N/A | Appearance | N/A |
Safety | Risk Codes | N/A | |
Molecular Structure | Hazard Symbols | N/A | |
Synonyms |
3,5-Pyridinedicarboxylicacid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester, dihydrochloride (9CI);CV4093;Calslot;Franidipine hydrochloride; |
Article Data | 8 |
Molecular Formula: C35H40Cl2N4O6
Formula Weight of Manidipine hydrochloride (89226-75-5): 683.62 g/mol
Synonyms: 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester hydrochloride ; 4-(diphenylmethyl)-1-piperazinyl)ethylmethylester,dihydrochloride ; 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester hydrochloride ; Calslot
IUPAC Name: 3-O-[2-(4-benzhydrylpiperazin-1-yl)ethyl] 5-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate dihydrochloride
Product Categories: Antihypertensive
Flash Point of Manidipine hydrochloride (89226-75-5): 390.4 °C
Boiling Point of Manidipine hydrochloride (89226-75-5): 722 °C at 760 mmHg
Vapour Pressure of Manidipine hydrochloride (89226-75-5): 1.07E-20 mmHg at 25 °C
1. Mouse LD50 intraperitoneal 62mg/kg (62mg/kg)
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17
2. Mouse LD50 oral 171mg/kg (171mg/kg)
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17
3. Mouse LD50 subcutaneous 340mg/kg (340mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17
4. Rat LD50 intraperitoneal 49mg/kg (49mg/kg)
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17
5. Rat LD50 oral 156mg/kg (156mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17
6. Rat LD50 subcutaneous 199mg/kg (199mg/kg)
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17
Percent Composition: C 61.49%, H 5.90%, N 8.20%, O 14.04%, Cl 10.37%